SynthesisHIV medicine2026
Temporal shifts in antiretroviral therapy regimens and metabolic outcomes in people living with HIV: A systematic review and meta-analysis.
Synthesis in HIV medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionAntiretroviral therapy (ART) for people living with HIV has led to dramatically reduced mortality and improved life expectancy. This achievement is accompanied by a higher risk for metabolic and other non-communicable diseases. The role and contribution of various ART regimens to adverse metabolic outcomes are not fully understood. We aimed to systematically evaluate the risk of metabolic outcomes associated with ART and to describe temporal trends in these risks across the modern ART era.
methodsFollowing our prespecified, registered protocol, we conducted a systematic review and meta-analysis of non-randomized observational studies, comparing ART-treated and ART-naïve adult people living with HIV and report the metabolic outcomes of interest. We extracted ART regimen combinations and metabolic outcomes and calculated pooled odds ratios (ORs) with 95% confidence intervals (95% CI) using a random-effects model. Temporal patterns were summarized by publication year and year of ART rollout.
resultsWe identified 6827 studies, in which 39 studies were eligible for analysis with information from 24 632 people living with HIV. Nucleoside reverse transcriptase inhibitors (NRTIs) were present throughout the review period. Non-nucleoside reverse transcriptase inhibitors (NNRTIs) predominated from the early 2000s to 2014, while protease inhibitors (PIs) dominated 1998-2014. Integrase strand transfer inhibitors (INSTIs) appeared from 2016 onwards. ART-treated adult people living with HIV had higher odds for metabolic syndrome (OR = 2.16, 95% CI = 1.33-3.52), while no statistically significant association was observed for type 2 diabetes mellitus (T2DM) (OR = 1.37, 95% CI = 0.65-2.90). DISCUSSION: Metabolic burden associated with modern HIV treatment shifted from lipid abnormalities to weight- and glucose-related outcomes. Meta-analysis results showed that ART-treated adults had nearly twice the odds of metabolic syndrome compared with ART-naïve adults. In contrast, our meta-analytic evidence did not demonstrate a statistically significant association between ART use and the odds of developing T2DM. Findings should be interpreted with caution given potential confounding by disease stage, access to healthcare and survivorship bias.
conclusionsART regimens and their metabolic outcomes have shifted over time. ART-treated adult people living with HIV had higher odds of metabolic syndrome than their ART-naïve peers. Given heterogeneity and residual confounding, robust, long-term studies would be needed to refine regimen-specific risks.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.